Literature DB >> 23455549

Multi-channel blockers for treatment of atrial fibrillation: an effective strategy?

David R Van Wagoner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23455549      PMCID： PMC3598420          DOI： 10.1093/cvr/cvt039

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN： 0008-6363            Impact factor:   10.787


× No keyword cloud information.
  11 in total

Review 1.  Heart disease and stroke statistics--2013 update: a report from the American Heart Association.

Authors:  Alan S Go; Dariush Mozaffarian; Véronique L Roger; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Sheila Franco; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Mark D Huffman; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; David Magid; Gregory M Marcus; Ariane Marelli; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Michael E Mussolino; Graham Nichol; Nina P Paynter; Pamela J Schreiner; Paul D Sorlie; Joel Stein; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2012-12-12       Impact factor: 29.690

Review 2.  Role of late sodium channel current block in the management of atrial fibrillation.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Cardiovasc Drugs Ther       Date:  2013-02       Impact factor: 3.727

3.  Outward K+ current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation.

Authors:  D R Van Wagoner; A L Pond; P M McCarthy; J S Trimmer; J M Nerbonne
Journal:  Circ Res       Date:  1997-06       Impact factor: 17.367

Review 4.  Ultra-rapid delayed rectifier channels: molecular basis and therapeutic implications.

Authors:  Ursula Ravens; Erich Wettwer
Journal:  Cardiovasc Res       Date:  2010-12-15       Impact factor: 10.787

5.  Atrial L-type Ca2+ currents and human atrial fibrillation.

Authors:  D R Van Wagoner; A L Pond; M Lamorgese; S S Rossie; P M McCarthy; J M Nerbonne
Journal:  Circ Res       Date:  1999-09-03       Impact factor: 17.367

Review 6.  Examining the safety of amiodarone.

Authors:  Pasquale Santangeli; Luigi Di Biase; John David Burkhardt; Rong Bai; Prasant Mohanty; Agnes Pump; Andrea Natale
Journal:  Expert Opin Drug Saf       Date:  2012-02-13       Impact factor: 4.250

7.  Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug.

Authors: 
Journal:  J Am Coll Cardiol       Date:  2003-07-02       Impact factor: 24.094

8.  Kv1.5 is an important component of repolarizing K+ current in canine atrial myocytes.

Authors:  David Fedida; Jodene Eldstrom; J Christian Hesketh; Michelle Lamorgese; Laurie Castel; David F Steele; David R Van Wagoner
Journal:  Circ Res       Date:  2003-09-18       Impact factor: 17.367

9.  Atrial selectivity in Na+channel blockade by acute amiodarone.

Authors:  Tomoyuki Suzuki; Mikio Morishima; Sara Kato; Norihiro Ueda; Haruo Honjo; Kaichiro Kamiya
Journal:  Cardiovasc Res       Date:  2013-01-22       Impact factor: 10.787

10.  Human electrophysiological and pharmacological properties of XEN-D0101: a novel atrial-selective Kv1.5/IKur inhibitor.

Authors:  John Ford; James Milnes; Erich Wettwer; Torsten Christ; Marc Rogers; Kathy Sutton; David Madge; Laszlo Virag; Norbert Jost; Zoltan Horvath; Klaus Matschke; Andras Varro; Ursula Ravens
Journal:  J Cardiovasc Pharmacol       Date:  2013-05       Impact factor: 3.105
View more
  1 in total

1.  Common Structural Pattern for Flecainide Binding in Atrial-Selective Kv1.5 and Nav1.5 Channels: A Computational Approach.

Authors:  Yuliet Mazola; José C E Márquez Montesinos; David Ramírez; Leandro Zúñiga; Niels Decher; Ursula Ravens; Vladimir Yarov-Yarovoy; Wendy González
Journal:  Pharmaceutics       Date:  2022-06-27       Impact factor: 6.525
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.